Milestone Pharmaceuticals Inc. (MIST): Results of Operations and Financial Condition
Milestone Pharmaceuticals Inc. (MIST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2614433d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage
How this was made
The 30-second read
Why it matters
Traders can update expectations for (1) commercial adoption and payer coverage, (2) clinical execution timing for ReVeRA-301, and (3) cash runway into H2 2027, which together shape risk/reward into upcoming regulatory and enrollment milestones.
Market read
The filing combines fresh commercial KPIs, a new clinical execution step (Phase 3 sites activated), and a cash runway update, which can drive near-term sentiment and positioning.
What to watch
Enrollment pace and regulatory pathway execution for the AFib-RVR sNDA are the key swing factors; commercial KPIs could plateau if payer coverage or prescriber adoption slows.
Background
This is an SEC 8-K with Q2 2026 results and corporate updates for Milestone Pharmaceuticals’ CARDAMYST (etripamil) nasal spray and its Phase 3 AFib-RVR program.
Ticker impact
Milestone reports CARDAMYST launch traction, formulary coverage growth to ~50% of lives, and activates Phase 3 ReVeRA-301 AFib-RVR sites.
Likely positive bias for the next session and into the investor call, with follow-through dependent on whether coverage and enrollment momentum persists.
The filing adds concrete commercial KPIs (prescribers, scripts, coverage) and a fresh clinical milestone (Phase 3 sites activated, first patient expected H2 2026), alongside a cash runway update into H2 2027.
Market effects
Adds a datapoint on commercialization momentum for intranasal etripamil in cardiovascular arrhythmias, which can influence sentiment toward small-cap specialty pharma execution.
Limited direct regional read-through beyond US commercial payer coverage and US-listed biotech risk appetite.
EMA decision timing for PSVT in Europe (H1 2027) and NMPA review in China keep the program on a global regulatory watchlist.
Counterpoint
Coverage is improving, but product revenue remains small and SG&A has surged, so near-term fundamentals may not yet justify a sustained rerating.
Key entities
- companyMilestone Pharmaceuticals Inc.
Nasdaq-listed biopharmaceutical company developing and commercializing etripamil nasal spray for arrhythmias.
- productCARDAMYST (etripamil) nasal spray
Commercial product launched for PSVT in mid-February 2026, with expanding payer coverage and prescription growth.
- clinical_trialReVeRA-301
Phase 3 registrational trial evaluating self-administered etripamil for AFib-RVR; sites activated and first patient enrollment expected in H2 2026.
- regulatorEuropean Medicines Agency (EMA)
Reviewing the PSVT marketing authorization application, with decision expected in H1 2027.
- regulatorChina National Medical Products Administration (NMPA)
Reviewing the PSVT NDA in China; partner Everest Medicines handles engagement.
